ibi351
innovent biologics
['sclc', 'solid tumor', 'ibi351', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nsclc', 'innovent']
innovent presents clinical data of phase i study for ibi351 (kras g12c inhibitor) as monotherapy for solid tumors at asco n=31 (25 nsclc, 5 crc, 1 pdac) - 30% &gt;=3 prior lines n=21 eval (16 nsclc+5crc): 9 pr by investigator ie orr 42.9% / dcr 81%.
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)